SAN DIEGO--(BUSINESS WIRE)---- $AKRO #AKRO--Robbins LLP is Investigating Allegations Akero Therapeutics, Inc. (AKRO) Misled Investors Regarding Viability and Efficacy of its Trial Drug Candidate
Related news